Visirna Therapeutics Files IPO Prospectus Following Establishment of China R&D Center and Advancement of siRNA Pipeline

Is a company based inChina, a global-focused small nucleic acid drug therapy company, aims to build a production with comprehensive capabilities in research and development, manufacturing, and commercialization.Visirna, a biopharmaceutical company, currently has three small nucleic acid drugs in clinical development targeting the cardiovascular and metabolic disease fields, holding a leading position among similar competitors.The company adopts an internationally coordinated clinical development and registration strategy, which helps accelerate the registration and market launch of products under research.

One of Visirna's existing shareholders, Arrowhead Pharmaceuticals, is a leading publicly traded biotechnology company in the industry. As a pioneer and leader in the small nucleic acid therapy sector, Arrowhead possesses extensive proprietary technology and intellectual property in this field. It has a robust and versatile drug discovery and development platform, along with a rich and advanced product pipeline.